IGC Pharma, Inc.IGC

IGC Pharma is developing MINT-AD and AHA AI platforms for Alzheimer's research and data harmonization.

“We are also developing two proprietary artificial intelligence (“AI”)-enabled platforms. MINT-AD is designed to support risk stratification and longitudinal assessment in AD using multimodal datasets and is intended as a clinical and research decision-support tool. The Agentic Harmonization Assistant (“AHA”) is designed to assist with the harmonization and analysis of fragmented biomedical datasets; we announced its beta version in June 2026. MINT-AD and AHA remain under development and have not been approved or cleared as diagnostic or therapeutic products.”

IGC Pharma is developing AHA agentic analytics platform to support its AI research efforts.

“3. Agentic Harmonization Assistant (“AHA”) to support MINT-AD and the Company’s broader AI research and development efforts, IGC Pharma has and is developing AHA, an agentic analytics and data harmonization architecture designed to support large-scale AD research.”

IGC Pharma is developing MINT-AD and AHA AI platforms for Alzheimer's and biomedical data analysis.

“The Company is developing a proprietary Multimodal Interpretable Transformer for Alzheimer’s Disease (“MINT-AD”). MINT-AD is an artificial intelligence (“AI”) platform designed to enhance the detection and management of Alzheimer’s disease (“AD”) by providing clinicians with scalable, interpretable, and predictive diagnostic support. The platform is engineered to transition AD diagnostics from specialized, high-cost environments—such as neurology clinics utilizing Positron Emission Tomography (“PET”) scans—to primary care settings, rural areas, and underserved populations, although there is no assurance we will be successful in this regard. MINT-AD is intended as a clinical and research decision-support tool and is not currently approved as a diagnostic device. In addition, the Company is developing the Agentic Harmonization Assistant (“AHA”), a proprietary artificial intelligence-enabled platform designed to assist with the harmonization and analysis of fragmented biomedical datasets. As of June 2026, the Company announced the beta version of AHA. MINT-AD and AHA remain under development and have not been approved or cleared as diagnostic or therapeutic products.”

IGC Pharma lists completing AHA and MINT-AD as a goal.

“Completing Agentic Harmonization Assistant (“AHA”) and MINT-AD.”

IGC Pharma announced beta version of its AHA AI platform in June 2026.

“On June 23, 2026, the Company announced the beta version of its proprietary Agentic Harmonization Assistant (“AHA”), an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer’s and aging-related datasets.”

IGC Pharma has developed and is developing AHA agentic analytics for Alzheimer’s research.

“3. Agentic Harmonization Assistant (“AHA”) to support of MINT-AD and the Company’s broader AI research and development efforts, IGC Pharma has and is developing AHA, an agentic analytics and data harmonization architecture designed to support large-scale Alzheimer’s disease research.”

IGC Pharma plans to complete Agentic Harmonization Assistant and MINT-AD.

“Completing Agentic Harmonization Assistant (“AHA”) and MINT-AD.”